A Message From Our Program Leader
Research in Neuro-oncology at HonorHealth Research Institute includes clinical studies evaluating treatments designed to extend survival. Precision oncologic care based on molecular signatures of individual tumors, including the use of organoids, will increase our treatment success. Additional treatment research protocols are in the pipeline and should enhance the standard of care.
About Our Program
The Neuro-oncology Program is committed to providing patients with Central Nervous System (CNS) tumors a comprehensive range of treatment options, including access to innovative clinical trials and advanced care protocols. We specialize in treating these complex conditions through a multidisciplinary approach that includes surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy. This collaborative model ensures that each patient receives personalized care that integrates both standard-of-care treatments and cutting-edge research opportunities.
Treatment plans are tailored to the tumor type, its location, and the patient’s overall health. Our program actively collaborates with pharmaceutical companies and academic institutions to initiate and participate in clinical trials across multiple phases. A dedicated team of neurosurgeons, neurologists, radiation oncologists, medical oncologists, radiologists, pathologists and other specialists work together to deliver the highest standard of care.
Regular multidisciplinary tumor board meetings are held to review new and complex cases, allowing for the development of individualized treatment strategies. Our team ensures the highest standards of patient care and safety and fosters a culture of continuous improvement, encouraging the adoption of innovative treatments and technologies.
We are deeply committed to advancing neuro-oncology through research, collaboration and compassionate care.
NeuroOncology Facts and Figures
The most lethal human tumor — glioblastoma — affects 1% of the population.
The blood brain barrier limits the use of most immunotherapies and chemotherapies in brain tumor treatment.
Nearly 1-in-3 brain tumors are malignant gliomas, 1-in-3 are metastatic from another source in the body, and 1-in-3 are benign meningiomas.
